[{"orgOrder":0,"company":"The Biovac Institute","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"SOUTH AFRICA","productType":"Vaccine","year":"2021","type":"Collaboration","leadProduct":"Tozinameran","moa":"SARS-CoV-2 spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"The Biovac Institute","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"The Biovac Institute \/ Pfizer","highestDevelopmentStatusID":"12","companyTruncated":"The Biovac Institute \/ Pfizer"},{"orgOrder":0,"company":"The Biovac Institute","sponsor":"International Vaccine Institute","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"SOUTH AFRICA","productType":"Vaccine","year":"2022","type":"Partnership","leadProduct":"Cholera Vaccine","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"The Biovac Institute","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"The Biovac Institute \/ International Vaccine Institute","highestDevelopmentStatusID":"4","companyTruncated":"The Biovac Institute \/ International Vaccine Institute"},{"orgOrder":0,"company":"The Biovac Institute","sponsor":"Wellcome","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"SOUTH AFRICA","productType":"Vaccine","year":"2022","type":"Funding","leadProduct":"Cholera Vaccine","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"The Biovac Institute","amount2":0.01,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.01,"dosageForm":"","sponsorNew":"The Biovac Institute \/ Wellcome","highestDevelopmentStatusID":"4","companyTruncated":"The Biovac Institute \/ Wellcome"}]

Find Clinical Drug Pipeline Developments & Deals by The Biovac Institute

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Antibody Engineering
                          Not Confirmed
                          Antibody Engineering
                          Not Confirmed

                          Details : The partnership with IVI aims to license and transfer technology with the ultimate aim of increasing production volumes of OCV (cholera vaccines) in order to reduce the critical shortage of vaccines needed to prevent cholera globally.

                          Brand Name : OCV

                          Molecule Type : Vaccine

                          Upfront Cash : Undisclosed

                          November 23, 2022

                          Lead Product(s) : Cholera Vaccine

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Preclinical

                          Sponsor : International Vaccine Institute

                          Deal Size : Undisclosed

                          Deal Type : Partnership

                          blank

                          02

                          Antibody Engineering
                          Not Confirmed
                          Antibody Engineering
                          Not Confirmed

                          Details : IVI developed the world’s first low-cost oral cholera vaccine (OCV). The partnership with IVI aims to license and transfer technology with the ultimate aim of increasing production volumes in order to reduce the critical shortage of vaccines needed to ...

                          Brand Name : OCV

                          Molecule Type : Vaccine

                          Upfront Cash : Undisclosed

                          November 22, 2022

                          Lead Product(s) : Cholera Vaccine

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Preclinical

                          Sponsor : Wellcome

                          Deal Size : $6.9 million

                          Deal Type : Funding

                          blank

                          03

                          Antibody Engineering
                          Not Confirmed
                          Antibody Engineering
                          Not Confirmed

                          Details : Biovac will perform manufacturing and distribution activities within Pfizer’s and BioNTech’s Covid Vaccine, BNT162b2's global supply chain and manufacturing network, which will now span three continents and include more than 20 manufacturing faciliti...

                          Brand Name : BNT162b2

                          Molecule Type : Vaccine

                          Upfront Cash : Undisclosed

                          July 21, 2021

                          Lead Product(s) : Tozinameran

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Approved

                          Sponsor : Pfizer Inc

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank